• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Medpace Holdings, Inc. Reports Third Quarter 2024 Results

    10/21/24 4:15:00 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $MEDP alert in real time by email
    • Revenue of $533.3 million in the third quarter of 2024 increased 8.3% from revenue of $492.5 million for the comparable prior-year period, representing a backlog conversion rate of 18.2%.
    • Net new business awards were $533.7 million in the third quarter of 2024, representing a decrease of 12.7% from net new business awards of $611.5 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.00x.
    • Third quarter of 2024 GAAP net income was $96.4 million, or $3.01 per diluted share, versus GAAP net income of $70.6 million, or $2.22 per diluted share, for the comparable prior-year period. Net income margin was 18.1% and 14.3% for the third quarter of 2024 and 2023, respectively.
    • EBITDA was $118.8 million for the third quarter of 2024, an increase of 31.7% from EBITDA of $90.2 million for the comparable prior-year period, resulting in an EBITDA margin of 22.3%.

    Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced financial results for the third quarter ended September 30, 2024.

    Third Quarter 2024 Financial Results

    Revenue for the three months ended September 30, 2024 increased 8.3% to $533.3 million, compared to $492.5 million for the comparable prior-year period. On a constant currency basis, revenue for the third quarter of 2024 increased 8.1% compared to the third quarter of 2023.

    Backlog as of September 30, 2024 increased 8.8% to $2,927.4 million from $2,689.5 million as of September 30, 2023. Net new business awards were $533.7 million, representing a net book-to-bill ratio of 1.00x for the third quarter of 2024, as compared to $611.5 million for the comparable prior-year period. The Company calculates the net book-to-bill ratio by dividing net new business awards by revenue.

    For the third quarter of 2024, total direct costs were $364.3 million, compared to total direct costs of $359.3 million in the third quarter of 2023. Selling, general and administrative (SG&A) expenses were $49.2 million in the third quarter of 2024, compared to SG&A expenses of $41.4 million in the third quarter of 2023.

    GAAP net income for the third quarter of 2024 was $96.4 million, or $3.01 per diluted share, versus GAAP net income of $70.6 million, or $2.22 per diluted share, for the third quarter of 2023. This resulted in a net income margin of 18.1% and 14.3% for the third quarter of 2024 and 2023, respectively.

    EBITDA for the third quarter of 2024 increased 31.7% to $118.8 million, or 22.3% of revenue, compared to $90.2 million, or 18.3% of revenue, for the comparable prior-year period. On a constant currency basis, EBITDA for the third quarter of 2024 increased 32.3% from the third quarter of 2023.

    A reconciliation of the Company's non-GAAP financial measures, including EBITDA and EBITDA margin to the corresponding GAAP measures is provided below.

    Year-to-Date 2024 Financial Results

    Revenue for the nine months ended September 30, 2024 was $1,572.5 million, and increased 13.3% on a reported basis and constant currency basis from the comparable prior-year period. Year-to-date 2024 GAAP net income was $287.4 million, or $8.96 per diluted share, compared to $204.5 million, or $6.42 per diluted share, for the comparable prior-year period. Year-to-date 2024 EBITDA was $346.7 million, or 22.0% of revenue, and increased 30.0% on a reported basis and 29.8% on a constant currency basis from the comparable prior-year period.

    Balance Sheet and Liquidity

    The Company's Cash and cash equivalents were $656.9 million at September 30, 2024, and the Company generated $149.1 million in cash flow from operating activities during the third quarter of 2024. There were no share repurchases in the third quarter of 2024. As of September 30, 2024, the Company had $308.8 million remaining under its authorized share repurchase program.

    2024 Financial Guidance

    The Company forecasts 2024 revenue in the range of $2.090 billion to $2.130 billion, representing growth of 10.8% to 12.9% over 2023 revenue of $1.886 billion. GAAP net income for full year 2024 is forecasted in the range of $376.0 million to $388.0 million. Additionally, full year 2024 EBITDA is expected in the range of $450.0 million to $470.0 million. Based on forecasted 2024 revenue of $2.090 billion to $2.130 billion and GAAP net income of $376.0 million to $388.0 million, diluted earnings per share (GAAP) is forecasted in the range of $11.71 to $12.09. This guidance assumes a full year 2024 tax rate of 15.5% to 16.5%, interest income of $24.4 million, and 32.1 million diluted shares outstanding. This guidance does not include the potential impact of any share repurchases the Company may make pursuant to the share repurchase program after September 30, 2024.

    Conference Call Details

    Medpace will host a conference call at 9:00 a.m. ET, Tuesday, October 22, 2024, to discuss its third quarter 2024 results.

    To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call.

    To access the conference call via webcast, visit the "Investors" section of Medpace's website at medpace.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. A supplemental slide presentation will also be available at the "Investors" section of Medpace's website prior to the start of the call.

    About Medpace

    Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace's mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 5,900 people across 43 countries as of September 30, 2024.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding our forecasted financial results and the effective tax rate used for non-GAAP adjustment purposes. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "guidance," "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "target," "forecast," "may," "could," "likely," "anticipate," "project," "goal," "objective," "potential," "range," "estimate," "preliminary," "opportunity," "outlook," "trend," "can," "might," "drives," "hope," "predict" and similar expressions, and variations or negatives of these words. However, the absence of these words does not mean that a statement is not forward-looking.

    These forward-looking statements are largely based on management's current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our financial condition, actual results, performance (including share price performance), or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the potential loss, delay or non-renewal of our contracts, or the non-payment by customers for services we have performed; the failure to convert backlog to revenue at our present or historical conversion rate(s); the failure to maintain or generate new business awards; fluctuation in our results between fiscal quarters and years; the risks and uncertainties related to disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases; decreased operating margins due to increased pricing pressure or other factors; our failure to perform our services in accordance with contractual requirements, government regulations and ethical considerations; the impact of underpricing our contracts, overrunning our cost estimates or failing to receive approval for or experiencing delays with documentation of change orders; our failure to increase our market share, grow our business, successfully execute our growth strategies or manage our growth effectively; the impact of a failure to retain key executives or other personnel or recruit experienced personnel; the risks associated with our information systems infrastructure, including potential cybersecurity breaches and other disruptions which could compromise patient information or our information; adverse results from customer or therapeutic area concentration; the risks associated with doing business internationally, including the effects of tariffs and trade wars; the risks associated with the Foreign Corrupt Practices Act and other anti-corruption laws; future net losses; the impact of changes in tax laws and regulations; our failure to attract suitable investigators and patients to our clinical trials; the liability risks associated with our research and development services, including risks of liability resulting from harm to patients; inadequate insurance coverage for our operations and indemnification obligations; fluctuations in exchange rates; general economic conditions, including inflation, in the markets in which we operate, including financial market conditions; the impact of unfavorable economic conditions, including conditions caused by the uncertain international economic environment and current and future international conflicts; the impact of a natural disaster or other catastrophic event; negative outsourcing trends in the biopharmaceutical industry and a reduction in aggregate expenditures and research and development budgets; our inability to compete effectively with other CROs; the impact of healthcare reform; the impact of consolidation in the biopharmaceutical industry; our failure to comply with federal, state and foreign healthcare laws; the effect of current and proposed laws and regulations regarding the protection of personal data; our potential involvement in costly intellectual property lawsuits; actions by regulatory authorities or customers to limit the scope of indications related to or withdraw an approved drug, biologic or medical device from the market; and the impact of industry-wide reputational harm to CROs. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all important factors on our business or the extent to which any factor, or combination of such factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make.

    These and other important factors discussed under the caption "Risk Factors" in Item 1A, Part I of our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. We cannot guarantee that any forward-looking statement will be realized. Achievement of anticipated results is subject to substantial risks, uncertainties and inaccurate assumptions. If known or unknown risks or uncertainties materialize or if underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events, developments or circumstances cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

    Non-GAAP Financial Measures

    Certain financial measures presented in this press release, such as EBITDA and EBITDA margin, are not recognized under generally accepted accounting principles in the United States of America, or U.S. GAAP. Management uses EBITDA and EBITDA margin or comparable metrics as a measurement used in evaluating our operating performance on a consistent basis, as a consideration to assess incentive compensation for our employees, for planning purposes, including the preparation of our internal annual operating budget, and to evaluate the performance and effectiveness of our operational strategies.

    EBITDA and EBITDA margin have important limitations as analytical tools and you should not consider them in isolation, or as a substitute for, analysis of our results as reported under U.S. GAAP. See the condensed consolidated financial statements included elsewhere in this release for our U.S. GAAP results. Additionally, for reconciliations of EBITDA and EBITDA margin to our closest reported U.S. GAAP measures, refer to the appendix of this press release.

    We believe that EBITDA and EBITDA margin are useful to provide additional information to investors about certain material non-cash and non-recurring items. While we believe these financial measures are commonly used by investors to evaluate our performance and that of our competitors, because not all companies use identical calculations, this presentation of EBITDA and EBITDA margin may not be comparable to other similarly titled measures of other companies and should not be considered as an alternative to performance measures derived in accordance with U.S. GAAP. EBITDA is calculated as net income attributable to Medpace Holdings, Inc. before income tax expense, interest expense, net, depreciation and amortization. EBITDA margin is calculated by dividing EBITDA by Revenue, net for each period. Our presentation of EBITDA and EBITDA margin should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items.

     

    MEDPACE HOLDINGS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

     

    (Amounts in thousands, except per share amounts)

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

     

    2024

     

    2023

     

    2024

     

    2023

    Revenue, net

    $

    533,317

     

     

    $

    492,499

     

     

    $

    1,572,465

     

    $

    1,387,441

     

    Operating expenses:

     

     

     

     

     

     

     

    Direct service costs, excluding depreciation and amortization

     

    171,540

     

     

     

    164,364

     

     

     

    514,573

     

     

    473,958

     

    Reimbursed out-of-pocket expenses

     

    192,769

     

     

     

    194,942

     

     

     

    579,904

     

     

    525,784

     

    Total direct costs

     

    364,309

     

     

     

    359,306

     

     

     

    1,094,477

     

     

    999,742

     

    Selling, general and administrative

     

    49,217

     

     

     

    41,407

     

     

     

    134,751

     

     

    118,838

     

    Depreciation

     

    7,158

     

     

     

    6,329

     

     

     

    20,663

     

     

    17,707

     

    Amortization

     

    360

     

     

     

    549

     

     

     

    1,082

     

     

    1,649

     

    Total operating expenses

     

    421,044

     

     

     

    407,591

     

     

     

    1,250,973

     

     

    1,137,936

     

    Income from operations

     

    112,273

     

     

     

    84,908

     

     

     

    321,492

     

     

    249,505

     

    Other income (expense), net:

     

     

     

     

     

     

     

    Miscellaneous (expense) income, net

     

    (1,025

    )

     

     

    (1,602

    )

     

     

    3,435

     

     

    (2,198

    )

    Interest income (expense), net

     

    7,528

     

     

     

    (105

    )

     

     

    17,113

     

     

    (2,332

    )

    Total other income (expense), net

     

    6,503

     

     

     

    (1,707

    )

     

     

    20,548

     

     

    (4,530

    )

    Income before income taxes

     

    118,776

     

     

     

    83,201

     

     

     

    342,040

     

     

    244,975

     

    Income tax provision

     

    22,350

     

     

     

    12,651

     

     

     

    54,672

     

     

    40,463

     

    Net income

    $

    96,426

     

     

    $

    70,550

     

     

    $

    287,368

     

    $

    204,512

     

    Net income per share attributable to common shareholders:

     

     

     

     

     

     

     

    Basic

    $

    3.11

     

     

    $

    2.30

     

     

    $

    9.28

     

    $

    6.65

     

    Diluted

    $

    3.01

     

     

    $

    2.22

     

     

    $

    8.96

     

    $

    6.42

     

    Weighted average common shares outstanding:

     

     

     

     

     

     

     

    Basic

     

    31,047

     

     

     

    30,629

     

     

     

    30,960

     

     

    30,723

     

    Diluted

     

    32,088

     

     

     

    31,762

     

     

     

    32,060

     

     

    31,839

     

     

    MEDPACE HOLDINGS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

     

    (Amounts in thousands, except share amounts)

     

     

     

     

    As of

     

    September 30,

    2024

     

    December 31,

    2023

    ASSETS

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    656,900

     

     

    $

    245,449

     

    Accounts receivable and unbilled, net

     

    311,466

     

     

     

    298,400

     

    Prepaid expenses and other current assets

     

    64,229

     

     

     

    49,979

     

    Total current assets

     

    1,032,595

     

     

     

    593,828

     

    Property and equipment, net

     

    124,058

     

     

     

    120,589

     

    Operating lease right-of-use assets

     

    130,547

     

     

     

    144,801

     

    Goodwill

     

    662,396

     

     

     

    662,396

     

    Intangible assets, net

     

    34,727

     

     

     

    35,809

     

    Deferred income taxes

     

    76,683

     

     

     

    74,435

     

    Other assets

     

    23,055

     

     

     

    24,970

     

    Total assets

    $

    2,084,061

     

     

    $

    1,656,828

     

    LIABILITIES AND SHAREHOLDERS' EQUITY

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    26,201

     

     

    $

    31,869

     

    Accrued expenses

     

    306,868

     

     

     

    292,961

     

    Advanced billings

     

    670,939

     

     

     

    559,860

     

    Other current liabilities

     

    37,346

     

     

     

    40,441

     

    Total current liabilities

     

    1,041,354

     

     

     

    925,131

     

    Operating lease liabilities

     

    128,277

     

     

     

    142,122

     

    Deferred income tax liability

     

    2,289

     

     

     

    2,404

     

    Other long-term liabilities

     

    30,702

     

     

     

    28,221

     

    Total liabilities

     

    1,202,622

     

     

     

    1,097,878

     

    Commitments and contingencies

     

     

     

    Shareholders' equity:

     

     

     

    Preferred stock - $0.01 par-value; 5,000,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023

     

    —

     

     

     

    —

     

    Common stock - $0.01 par-value; 250,000,000 shares authorized at September 30, 2024 and December 31, 2023; 31,081,601 and 30,752,292 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively

     

    311

     

     

     

    308

     

    Treasury stock - 70,073 and 70,573 shares at September 30, 2024 and December 31, 2023, respectively

     

    (12,235

    )

     

     

    (12,322

    )

    Additional paid-in capital

     

    836,903

     

     

     

    802,681

     

    Retained earnings (Accumulated deficit)

     

    65,636

     

     

     

    (221,645

    )

    Accumulated other comprehensive loss

     

    (9,176

    )

     

     

    (10,072

    )

    Total shareholders' equity

     

    881,439

     

     

     

    558,950

     

    Total liabilities and shareholders' equity

    $

    2,084,061

     

     

    $

    1,656,828

     

     

    MEDPACE HOLDINGS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

     

    (Amounts in thousands)

    Nine Months Ended

    September 30,

     

    2024

     

    2023

    CASH FLOWS FROM OPERATING ACTIVITIES:

     

     

     

    Net income

    $

    287,368

     

     

    $

    204,512

     

    Adjustments to reconcile net income to net cash provided by operating activities:

     

     

     

    Depreciation

     

    20,663

     

     

     

    17,707

     

    Amortization

     

    1,082

     

     

     

    1,649

     

    Stock-based compensation expense

     

    19,625

     

     

     

    15,351

     

    Noncash lease expense

     

    17,305

     

     

     

    14,579

     

    Deferred income tax benefit

     

    (2,433

    )

     

     

    (11,308

    )

    Other

     

    (3,836

    )

     

     

    821

     

    Changes in assets and liabilities:

     

     

     

    Accounts receivable and unbilled, net

     

    (13,032

    )

     

     

    (39,314

    )

    Prepaid expenses and other current assets

     

    (11,108

    )

     

     

    (8,954

    )

    Accounts payable

     

    (3,029

    )

     

     

    (921

    )

    Accrued expenses

     

    13,933

     

     

     

    54,923

     

    Advanced billings

     

    111,079

     

     

     

    56,026

     

    Lease liabilities

     

    (15,417

    )

     

     

    (14,433

    )

    Other assets and liabilities, net

     

    (4,051

    )

     

     

    (13,659

    )

    Net cash provided by operating activities

     

    418,149

     

     

     

    276,979

     

    CASH FLOWS FROM INVESTING ACTIVITIES:

     

     

     

    Property and equipment expenditures

     

    (28,905

    )

     

     

    (26,662

    )

    Other

     

    8,159

     

     

     

    30

     

    Net cash used in investing activities

     

    (20,746

    )

     

     

    (26,632

    )

    CASH FLOWS FROM FINANCING ACTIVITIES:

     

     

     

    Proceeds from stock option exercises

     

    14,600

     

     

     

    9,855

     

    Repurchases of common stock

     

    —

     

     

     

    (144,020

    )

    Proceeds from revolving loan

     

    —

     

     

     

    105,000

     

    Payments on revolving loan

     

    —

     

     

     

    (155,000

    )

    Net cash provided by (used in) financing activities

     

    14,600

     

     

     

    (184,165

    )

    EFFECT OF EXCHANGE RATES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH

     

    (552

    )

     

     

    760

     

    INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH

     

    411,451

     

     

     

    66,942

     

    CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period

     

    245,449

     

     

     

    28,265

     

    CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period

    $

    656,900

     

     

    $

    95,207

     

     

    MEDPACE HOLDINGS, INC. AND SUBSIDIARIES

    RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED)

     

    (Amounts in thousands)

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

     

    2024

     

    2023

     

    2024

     

    2023

    RECONCILIATION OF GAAP NET INCOME TO EBITDA

     

     

     

     

     

     

     

    Net income (GAAP)

    $

    96,426

     

     

    $

    70,550

     

     

    $

    287,368

     

     

    $

    204,512

     

    Interest (income) expense, net

     

    (7,528

    )

     

     

    105

     

     

     

    (17,113

    )

     

     

    2,332

     

    Income tax provision

     

    22,350

     

     

     

    12,651

     

     

     

    54,672

     

     

     

    40,463

     

    Depreciation

     

    7,158

     

     

     

    6,329

     

     

     

    20,663

     

     

     

    17,707

     

    Amortization

     

    360

     

     

     

    549

     

     

     

    1,082

     

     

     

    1,649

     

    EBITDA (Non-GAAP)

    $

    118,766

     

     

    $

    90,184

     

     

    $

    346,672

     

     

    $

    266,663

     

    Net income margin (GAAP)

     

    18.1

    %

     

     

    14.3

    %

     

     

    18.3

    %

     

     

    14.7

    %

    EBITDA margin (Non-GAAP)

     

    22.3

    %

     

     

    18.3

    %

     

     

    22.0

    %

     

     

    19.2

    %

    FY 2024 GUIDANCE RECONCILIATION (UNAUDITED)

     

    (Amounts in millions, except per share amounts)

    Forecast 2024

     

    Net Income

     

    Net income per diluted share

     

    Low

     

    High

     

    Low

     

    High

    Net income and net income per diluted share (GAAP)

    $

    376.0

     

     

    $

    388.0

     

     

    $

    11.71

     

    $

    12.09

    Income tax provision

     

    68.6

     

     

     

    76.6

     

     

     

     

     

    Interest income, net

     

    (24.4

    )

     

     

    (24.4

    )

     

     

     

     

    Depreciation

     

    28.4

     

     

     

    28.4

     

     

     

     

     

    Amortization

     

    1.4

     

     

     

    1.4

     

     

     

     

     

    EBITDA (Non-GAAP)

    $

    450.0

     

     

    $

    470.0

     

     

     

     

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241021984442/en/

    Get the next $MEDP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MEDP

    DatePrice TargetRatingAnalyst
    4/22/2025Outperform → Mkt Perform
    William Blair
    4/14/2025$328.00Buy → Hold
    TD Cowen
    3/24/2025$330.00Market Perform
    Leerink Partners
    10/23/2024$413.00 → $349.00Outperform → Neutral
    Robert W. Baird
    10/14/2024Buy
    Redburn Atlantic
    9/27/2024$420.00 → $350.00Buy → Neutral
    UBS
    9/25/2024$415.00 → $345.00Buy → Hold
    Jefferies
    8/1/2024$415.00Hold
    Truist
    More analyst ratings

    $MEDP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Medpace Holdings Inc. (Amendment)

      SC 13D/A - Medpace Holdings, Inc. (0001668397) (Subject)

      3/8/24 4:28:58 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D/A filed by Medpace Holdings Inc. (Amendment)

      SC 13D/A - Medpace Holdings, Inc. (0001668397) (Subject)

      2/28/24 5:04:01 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by Medpace Holdings Inc. (Amendment)

      SC 13G/A - Medpace Holdings, Inc. (0001668397) (Subject)

      2/13/24 5:09:38 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MEDP
    Financials

    Live finance-specific insights

    See more
    • Medpace Holdings, Inc. Reports First Quarter 2025 Results

      Revenue of $558.6 million in the first quarter of 2025 increased 9.3% from revenue of $511.0 million for the comparable prior-year period, representing a backlog conversion rate of 19.2%. Net new business awards were $500.0 million in the first quarter of 2025, representing a decrease of 18.8% from net new business awards of $615.6 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.90x. First quarter of 2025 GAAP net income was $114.6 million, or $3.67 per diluted share, versus GAAP net income of $102.6 million, or $3.20 per diluted share, for the comparable prior-year period. Net income margin was 20.5% and 20.1% for the first quarter of 2025

      4/21/25 4:15:00 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Medpace Holdings, Inc. to Report First Quarter 2025 Financial Results on April 21, 2025

      Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its first quarter 2025 financial results after the market close on Monday, April 21, 2025. The Company will host a conference call the following morning, Tuesday, April 22, 2025, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used

      3/18/25 4:05:00 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Results

      Revenue of $536.6 million in the fourth quarter of 2024 increased 7.7% from revenue of $498.4 million for the comparable prior-year period, representing a backlog conversion rate of 18.3%. Net new business awards were $529.7 million in the fourth quarter of 2024, representing a decrease of 13.8% from net new business awards of $614.7 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.99x. Fourth quarter of 2024 GAAP net income was $117.0 million, or $3.67 per diluted share, versus GAAP net income of $78.3 million, or $2.46 per diluted share, for the comparable prior-year period. Net income margin was 21.8% and 15.7% for the fourth quarter of

      2/10/25 4:15:00 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MEDP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $MEDP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Medpace downgraded by William Blair

      William Blair downgraded Medpace from Outperform to Mkt Perform

      4/22/25 10:17:27 AM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Medpace downgraded by TD Cowen with a new price target

      TD Cowen downgraded Medpace from Buy to Hold and set a new price target of $328.00

      4/14/25 8:14:21 AM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Leerink Partners initiated coverage on Medpace with a new price target

      Leerink Partners initiated coverage of Medpace with a rating of Market Perform and set a new price target of $330.00

      3/24/25 8:40:00 AM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Zander Dani S.

      4 - Medpace Holdings, Inc. (0001668397) (Issuer)

      5/20/25 4:59:16 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Mccarthy Cornelius P. Iii

      4 - Medpace Holdings, Inc. (0001668397) (Issuer)

      5/20/25 4:51:25 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Kraft Robert O.

      4 - Medpace Holdings, Inc. (0001668397) (Issuer)

      5/20/25 4:45:08 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MEDP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Medpace Holdings, Inc. Reports First Quarter 2025 Results

      Revenue of $558.6 million in the first quarter of 2025 increased 9.3% from revenue of $511.0 million for the comparable prior-year period, representing a backlog conversion rate of 19.2%. Net new business awards were $500.0 million in the first quarter of 2025, representing a decrease of 18.8% from net new business awards of $615.6 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.90x. First quarter of 2025 GAAP net income was $114.6 million, or $3.67 per diluted share, versus GAAP net income of $102.6 million, or $3.20 per diluted share, for the comparable prior-year period. Net income margin was 20.5% and 20.1% for the first quarter of 2025

      4/21/25 4:15:00 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Medpace Holdings, Inc. to Report First Quarter 2025 Financial Results on April 21, 2025

      Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its first quarter 2025 financial results after the market close on Monday, April 21, 2025. The Company will host a conference call the following morning, Tuesday, April 22, 2025, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used

      3/18/25 4:05:00 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Results

      Revenue of $536.6 million in the fourth quarter of 2024 increased 7.7% from revenue of $498.4 million for the comparable prior-year period, representing a backlog conversion rate of 18.3%. Net new business awards were $529.7 million in the fourth quarter of 2024, representing a decrease of 13.8% from net new business awards of $614.7 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.99x. Fourth quarter of 2024 GAAP net income was $117.0 million, or $3.67 per diluted share, versus GAAP net income of $78.3 million, or $2.46 per diluted share, for the comparable prior-year period. Net income margin was 21.8% and 15.7% for the fourth quarter of

      2/10/25 4:15:00 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MEDP
    Leadership Updates

    Live Leadership Updates

    See more
    • Medpace Holdings, Inc. Announces Senior Leadership Changes

      Appointment of Jesse Geiger as President and Kevin Brady as Chief Financial Officer Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced the appointment of Jesse Geiger as president and Kevin Brady as chief financial officer, effective August 1, 2021. August Troendle will continue to serve as Medpace's chairman and chief executive officer. Geiger joined Medpace in 2007 as corporate controller and became chief financial officer in 2011. In 2014, Geiger expanded his role to include chief operating officer of laboratory operations. Geiger will continue to report to August Troendle. The newly created position of president will allow Troendle to continue to focus on the overall lon

      7/26/21 4:15:00 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MEDP
    SEC Filings

    See more
    • SEC Form 8-K filed by Medpace Holdings Inc.

      8-K - Medpace Holdings, Inc. (0001668397) (Filer)

      5/16/25 5:11:00 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 144 filed by Medpace Holdings Inc.

      144 - Medpace Holdings, Inc. (0001668397) (Subject)

      4/24/25 2:13:57 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 10-Q filed by Medpace Holdings Inc.

      10-Q - Medpace Holdings, Inc. (0001668397) (Filer)

      4/22/25 4:02:48 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MEDP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • General Counsel & Corp. Secy. Ewald Stephen P bought $652 worth of shares (2 units at $326.11), increasing direct ownership by 0.01% to 13,343 units (SEC Form 4)

      4 - Medpace Holdings, Inc. (0001668397) (Issuer)

      2/28/25 4:39:05 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care